A comparison of the accuracy of the corpuscular fragility and mean corpuscular volume tests for the alpha-thalassemia 1 and beta-thalassemia traits

Objective: To compare the accuracy of the osmotic fragility test (OFT) and mean corpuscular volume (MCV) calculation when screening for the α-thalassemia 1 and/or β-thalassemia trait. Method: In this cross-sectional study, blood samples from 328 apparently healthy pregnant women were sent on the sam...

Full description

Saved in:
Bibliographic Details
Main Authors: Supatra Sirichotiyakul, Chanane Wanapirak, Kasemsri Srisupundit, Suchaya Luewan, Theera Tongsong
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=70249120655&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/59881
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Description
Summary:Objective: To compare the accuracy of the osmotic fragility test (OFT) and mean corpuscular volume (MCV) calculation when screening for the α-thalassemia 1 and/or β-thalassemia trait. Method: In this cross-sectional study, blood samples from 328 apparently healthy pregnant women were sent on the same day to separate laboratories for the OFT (performed using a glycerol 0.45%, phosphate-buffered, sodium chloride solution) and MCV testing (by means of a standard automated hematology analyzer). A polymerase chain reaction was also performed to positively diagnose α-thalassemia 1 carriers, and a quantitative HbA2test to positively diagnose β-thalassemia carriers. Results: Sensitivity and specificity were 95.0% and 86% for the OFT; and based on the cut-off point of 78.1 fL derived from the ROC curve, they were 93% and 93.4% for MCV calculation. The latter test was found to be slightly more accurate than the OFT in predicting the presence of the α-thalassemia 1 and/or β-thalassemia trait. Conclusion: Both tests have high screening sensitivity for the α-thalassemia 1 and/or β-thalassemia traits, and their simplicity and very low cost make them attractive as screening tests for large populations. Since MCV seems to provide fewer false-positive results, it may be the first choice wherever an automated hematology analyzer calculating MCV is available. © 2009.